Stop TB Partnership

Information on Delamanid

In 2016, the StopTB Partnership and Otsuka announced an innovative public-private partnership to allow all countries eligible for financing TB activities through the Global Fund to access delamanid through the Global Drug Facility.

Delamanid is approved by a Stringent Regulatory Authority (European Medicines Agency [EMA] and Japan).

The World Health Organization (WHO) issued Interim Guidance on the use of Delamanid in 2014 and Interim Guidance on the use of Delamanid in children and adolescents in 2016. WHO has also released a policy implementation package for introduction of new medicines and regimens.

If you need to report any delamanid adverse effects, please download the adverse event form and send it to dlmae@stoptb.org.

For an update on the scale-up of delamanid through GDF, please see the reports below:

If you have any additional questions related to ordering delamanid, please address your inquires to your Country Support Officer or dlm@stoptb.org.

Iso

GDF is ISO 9001:2000 compliant for provision of quality-assured anti-TB drugs and related services to eligible national TB control programmes.